Rhythm Pharmaceuticals Inc. (RYTM) experienced a sharp decline, with its stock price plummeting 5.30% during Friday's intraday session.
The sell-off coincided with several Wall Street analysts revising their price targets downward for the biopharmaceutical company. Needham cut its target to $139 from $148, RBC lowered its target to $140 from $145, and Wells Fargo reduced its target to $136 from $145.
While some firms maintained positive ratings on the stock, including Guggenheim (Buy) and Citizens JMP (Market Outperform), the collective downward adjustments in valuation benchmarks contributed to negative investor sentiment and the session's price drop.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.